"AI Therapeutics Announces Initiation of a Phase II Clinical Trial of AIT-101 for Treatment of ALS," published by AI Therapeutics
AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the initiation of a Phase II study for a promising new approach to treat amyotrophic lateral sclerosis (ALS).
